Effects of canagliflozin on biomarkers of cardiovascular stress in older patients with type 2 diabetes

被引：0
|
作者：
Sattar, N. [1 ]
Januzzi, J. L. [2 ]
Butler, J. [3 ]
Jarolim, P. [4 ]
Vijapurkar, U. [5 ]
Merton, K. W. [6 ]
Ren, J. [6 ]
Canovatchel, W. [5 ]
Desai, M. [5 ]
Davies, M. J. [6 ]
机构：
[1] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[3] SUNY Stony Brook, Cardiol Div, Stony Brook, NY 11794 USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[5] Janssen Res & Dev LLC, Raritan, NJ USA
[6] Janssen Sci Affairs LLC, Titusville, FL USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
913
引用
收藏
页码：S424 / S424
页数：1
相关论文
共 50 条
  • [1] Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Desai, Mehul
    Davies, Michael J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (06) : 704 - 712
  • [2] Effects of Canagliflozin (CANA) on Biomarkers of Cardiovascular (CV) Stress in Older Patients with Type 2 Diabetes Mellitus (T2DM)
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Merton, Katherine W.
    Ren, Jimmy
    Canovatchel, William
    Desai, Mehul
    Davies, Michael J.
    [J]. DIABETES, 2017, 66 : LB40 - LB40
  • [3] Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Budoff, Matthew J.
    Wilding, John P. H.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [4] Renal effects of canagliflozin in patients with Type 2 diabetes
    Wong, Yip Fong
    Shao, Yanli
    Sum, Chee Fang
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S119 - S120
  • [5] EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Van Gaal, Luc
    Garvey, Tim
    Leiter, Lawrence
    Vijapurkar, Ujjwala
    List, James
    Cuddihy, Robert
    Ren, Jimmy
    Davies, Michael
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1672 - 1672
  • [6] Canagliflozin and cardiovascular outcomes in Type 2 diabetes
    Sarraju, Ashish
    Spencer-Bonilla, Gabriela
    Rodriguez, Fatima
    Mahaffey, Kenneth W.
    [J]. FUTURE CARDIOLOGY, 2020, 17 (01) : 39 - 48
  • [7] Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes
    Van Gaal, L.
    Garvey, W. T.
    Leiter, L. A.
    Vijapurkar, U.
    List, J.
    Cuddihy, R.
    Ren, J.
    Davies, M. J.
    [J]. DIABETOLOGIA, 2017, 60 : S413 - S414
  • [8] Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
    Garvey, W. Timothy
    Van Gaal, Luc
    Leiter, Lawrence A.
    Vijapurkar, Ujjwala
    List, James
    Cuddihy, Robert
    Ren, Jimmy
    Davies, Michael J.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 85 : 32 - 37
  • [9] Effects of canagliflozin on serum magnesium in patients with type 2 diabetes
    Gilbert, R.
    Mende, C.
    Vijapurkar, U.
    Sha, S.
    Davies, M. J.
    Desai, M.
    [J]. DIABETOLOGIA, 2016, 59 : S350 - S351
  • [10] Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Guthrie, Robert
    [J]. POSTGRADUATE MEDICINE, 2018, 130 (02) : 149 - 153
12345